Saint Louis

Double-Digit Sales Growth From Larger Tires is Easing Market Challenges, Reports Circana

Retrieved on: 
Monday, June 26, 2023

CHICAGO, June 26, 2023 /PRNewswire-PRWeb/ -- Replacement tires with a rim diameter of under 18 inches account for the majority of retail sales in the U.S., but larger rim-diameter tires are delivering growth in the challenged market. Unit sales of replacement passenger-car and light-truck tires with rim diameters of 18 inches or larger grew 10% in February 2023, year over year, according to Circana, formerly IRI and The NPD Group.

Key Points: 
  • Replacement tires with a rim diameter of under 18 inches account for the majority of retail sales in the U.S., but larger rim-diameter tires are delivering growth in the challenged market.
  • Unit sales of replacement passenger-car and light-truck tires with rim diameters of 18 inches or larger grew 10% in February 2023, year over year, according to Circana, formerly IRI and The NPD Group.
  • CHICAGO, June 26, 2023 /PRNewswire-PRWeb/ -- Replacement tires with a rim diameter of under 18 inches account for the majority of retail sales in the U.S., but larger rim-diameter tires are delivering growth in the challenged market.
  • Unit sales of replacement passenger-car and light-truck tires with rim diameters of 18 inches or larger grew 10% in February 2023, year over year, according to Circana , formerly IRI and The NPD Group.

Dusit Hotels and Resorts all set for Japan and Europe debut - plus more new properties slated to open in key destinations this year

Retrieved on: 
Thursday, February 2, 2023

BANGKOK, Feb. 2, 2023 /PRNewswire/ -- Dusit Hotels and Resorts under Dusit International, one of Thailand's leading hotel and property development companies, has announced its expansion plans for 2023, including debuting its unique brand of Thai-inspired gracious hospitality in Japan and Europe – and further expanding its global footprint with strategic openings in China, India, Kenya, Nepal, and Thailand.

Key Points: 
  • A second phase, including 250 guest rooms and villas, is set to follow in 2024.
  • Designed to be a functional business hotel, the property features an all-day dining restaurant along with meeting facilities for small and midscale events.
  • Catering to business and leisure travellers, the hotel boasts a sleek, modern design that embodies the upscale nature of the dusitD2 brand.
  • A stunning lakeside restaurant, which also features a signature Dusit Gourmet outlet serving all kinds of freshly baked treats, will open ahead of the resort in Q2.

Dusit Hotels and Resorts all set for Japan and Europe debut - plus more new properties slated to open in key destinations this year

Retrieved on: 
Thursday, February 2, 2023

BANGKOK, Feb. 2, 2023 /PRNewswire/ -- Dusit Hotels and Resorts under Dusit International, one of Thailand's leading hotel and property development companies, has announced its expansion plans for 2023, including debuting its unique brand of Thai-inspired gracious hospitality in Japan and Europe – and further expanding its global footprint with strategic openings in China, India, Kenya, Nepal, and Thailand.

Key Points: 
  • A second phase, including 250 guest rooms and villas, is set to follow in 2024.
  • Designed to be a functional business hotel, the property features an all-day dining restaurant along with meeting facilities for small and midscale events.
  • Catering to business and leisure travellers, the hotel boasts a sleek, modern design that embodies the upscale nature of the dusitD2 brand.
  • A stunning lakeside restaurant, which also features a signature Dusit Gourmet outlet serving all kinds of freshly baked treats, will open ahead of the resort in Q2.

Stereotaxis Robotic Technology Reduces Incidence of Silent Cerebral Embolism During Atrial Fibrillation Ablation in New Peer-Reviewed Publication

Retrieved on: 
Wednesday, December 8, 2021

All patients received cerebral magnetic resonance imaging within 48 hours before and after the ablation procedure to assess cerebral embolism.

Key Points: 
  • All patients received cerebral magnetic resonance imaging within 48 hours before and after the ablation procedure to assess cerebral embolism.
  • Patients treated using RMN had greater than 82% reduced incidence of silent cerebral embolism (SCE) at 5.77% compared to 32.26% in patients treated with manual catheter ablation (p
  • The study concluded, ablation technology is the only independent risk factor of SCEs, and RMN can significantly reduce the incidence of SCEs resulting from AF ablation.
  • Stereotaxis Robotic Magnetic Navigation technology introduces the benefits of robotic precision and safety to cardiac ablation, a common, minimally invasive procedure to treat arrhythmias.

Stereotaxis to Host Inaugural Innovation Day – Pioneering Endovascular Robotics

Retrieved on: 
Thursday, November 18, 2021

ST. LOUIS, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it will host an inaugural Innovation Day by live webcast on December 13.

Key Points: 
  • ST. LOUIS, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it will host an inaugural Innovation Day by live webcast on December 13.
  • The event will include presentations of the companys innovation pipeline by members of Stereotaxis leadership with a live Q&A session.
  • We are excited to share Stereotaxis next wave of innovations and the transformative impact these innovations will have on the advancement of endovascular surgery, said David Fischel, Chairman and CEO of Stereotaxis.
  • Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention.

BJC HealthCare Becomes First Health Care System in Midwest to Adopt Latest Robotic Technology for Arrhythmia Treatment

Retrieved on: 
Monday, November 15, 2021

With this equipment, BJC becomes the first hospital system in the midwest providing the latest robotic technology to treat cardiac arrhythmia, and Missouri Baptist Medical Center becomes the first hospital to successfully treat patients with the Genesis RMN system in the region.

Key Points: 
  • With this equipment, BJC becomes the first hospital system in the midwest providing the latest robotic technology to treat cardiac arrhythmia, and Missouri Baptist Medical Center becomes the first hospital to successfully treat patients with the Genesis RMN system in the region.
  • Robotic Magnetic Navigation introduces the benefits of robotic precision and safety to cardiac ablation, a common, minimally invasive procedure to treat arrhythmias.
  • The Genesis RMN system consists of two robotically controlled magnets, a flexible catheter with a magnetic tip, and an operating console.
  • Stereotaxis(NYSE: STXS) is the global leader in innovative robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures.

Stereotaxis Reports 2021 Third Quarter Financial Results

Retrieved on: 
Thursday, November 11, 2021

ST. LOUIS, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the third quarter ended September 30, 2021.

Key Points: 
  • ST. LOUIS, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the third quarter ended September 30, 2021.
  • We are confident in the transformative impact these innovations will have on patients, physicians, providers, and on Stereotaxis strategic and financial future.
  • Revenue for the third quarter of 2021 totaled $9.1 million, up 5% from $8.7 million in the prior year third quarter.
  • Negative free cash flow for the third quarter was ($1.5) million, compared to ($0.2) million in the prior year third quarter.

Stereotaxis Technology, Clinical Value and Innovations to be Highlighted at Society for Cardiac Robotic Navigation Meeting

Retrieved on: 
Monday, November 8, 2021

SCRN was formed with the mission to advance clinical awareness, scientific research and technology innovation for robotic technologies in cardiology.

Key Points: 
  • SCRN was formed with the mission to advance clinical awareness, scientific research and technology innovation for robotic technologies in cardiology.
  • The SCRN meeting hosts cardiologists, fellows, innovators, industry leaders and scientists to debate, discuss, challenge, share, educate and learn with peers.
  • The hybrid in-person and virtual event includes several presentations on Stereotaxis technology, clinical value and innovations.
  • We are honored to join such a prestigious group of physicians and thought leaders at the Society for Cardiac Robotic Navigations annual meeting, said David Fischel, chairman and CEO of Stereotaxis.

Stifel Declares Quarterly Common Stock Cash Dividend and Declares Preferred Stock Cash Dividend

Retrieved on: 
Wednesday, November 3, 2021

The Board of Directors also declared a quarterly cash dividend on the outstanding shares of its 6.25% Non-Cumulative Perpetual Preferred Stock, Series B (the Series B Preferred Stock), 6.125% Non-Cumulative Perpetual Preferred Stock, Series C (the Series C Preferred Stock), and 4.50% Non-Cumulative Perpetual Preferred Stock, Series D (the Series D Preferred Stock).

Key Points: 
  • The Board of Directors also declared a quarterly cash dividend on the outstanding shares of its 6.25% Non-Cumulative Perpetual Preferred Stock, Series B (the Series B Preferred Stock), 6.125% Non-Cumulative Perpetual Preferred Stock, Series C (the Series C Preferred Stock), and 4.50% Non-Cumulative Perpetual Preferred Stock, Series D (the Series D Preferred Stock).
  • The declared cash dividend on the Series B Preferred Stock, Series C Preferred Stock, and Series D Preferred Stock is for the period from September 15, 2021, up to, but excluding, December 15, 2021.
  • The declared cash dividend equated to approximately $0.390625 per depositary share, or $390.625 per share of the Series B Preferred Stock outstanding.
  • The declared cash dividend equated to approximately $0.3828125 per depositary share, or $382.8125 per share of the Series C Preferred Stock outstanding.